Not yet recruitingInterventionalPhase 2Last updated Aug 14, 2026

Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel

A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy

Overview

ClinicalTrials.gov ID: NCT07765446
Lead Sponsor: Sironax USA, Inc.INDUSTRY
Brief Summary: This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).
Study Type

Status

Overall Status: Not yet recruiting
Start Date: Aug 3, 2026Estimated
Primary Completion Date: Dec 31, 2027Estimated
Completion Date: Dec 31, 2027Estimated

Study Record Dates

First Submitted: Jul 31, 2026
First Submitted that Met QC Criteria: Aug 10, 2026
First Posted: Aug 14, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 10, 2026
Last Update Posted: Aug 14, 2026Actual
Last Verified: Aug 2026

NCT00511849Completed

Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

NCT01525602Completed

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

NCT02412722Completed

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

NCT01326767Completed

Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring

NCT00088114Completed

STA-4783 and Paclitaxel for Treatment of Solid Tumors

NCT06632574Recruiting

A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors